TASK DEFINITION: Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.
PROBLEM: Biotechnology company Alkermes said earlier in the day that  it expected Lilly to drop out of their program to develop an  inhaled insulin treatment for diabetes, sending Alkermes shares  down more than 9 percent. Lilly’s decision marks the third setback in recent months  for inhaled insulin formulations, once deemed potential  blockbuster products because of their greater convenience than  standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the  alcohol addiction drug Vivitrol, said Lilly has the right to  terminate its license to the inhaled treatment, Air Insulin, at  its discretion. “While Lilly may elect not to commercialize Air Insulin,  Alkermes believes that the phase 3 safety and efficacy trials  should be completed,” Alkermes said in a statement. After Lilly’s announcement, the company said it was  evaluating the impact of the termination, which will become  effective in 90 days. Indianapolis-based Lilly said its decision was not due to  safety concerns, “but rather was a result of increasing  uncertainties in the regulatory environment, and a thorough  evaluation of the evolving commercial and clinical potential of  the product compared to existing medical therapies.”    Lilly Chief Operating Officer John Lechleiter said in a  statement that the company is beginning the process of halting  ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of  around $90 million to $120 million, or 5 cents to 7 cents per  share. The company said its adjusted earnings per share outlook  remains unchanged at $3.85 to $4.00, while net earnings will  range from $3.73 to $3.90. Lilly’s action comes just five months after Pfizer Inc  abandoned Exubera, the first approved inhaled form of insulin,  and returned rights to the product to longtime partner Nektar  Therapeutics. Exubera had dismal sales because patients were turned off  by the clumsy device used to administer the powdered insulin  and because doctors were concerned by the drug’s tendency to  slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with  Reuters in October, said Air Insulin may have similar effects  on lung function. “We’re assuming that pulmonary insulins in that regard are  all pretty much the same,” he said, although a conclusive  picture of Air Insulin’s safety will not emerge until two-year  safety trials of the product end later this year. A second setback for inhaled insulin came in January, when  Novo Nordisk said it was halting development of its AERx  product, meant to deliver inhaled droplets. The Danish  drugmaker said AERx did not have adequate sales potential,  given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly’s  abandonment of AIR Insulin made good business sense. “We are not (at) all surprised, and have never been strong  advocates of the pulmonary insulin agents, following the poor  launch and ultimate demise of Pfizer and Nektar’s Exubera and  Novo Nordisk’s termination of its AERx program,” Rubin said in  a research note. Rubin said Alkermes, known for its drug-delivery  technology, is unlikely to continue development of Air Insulin  without Lilly, “given that this represents the third  termination of a pulmonary insulin drug.”    But she said the sharp drop in Alkermes shares represented  a buying opportunity for investors because Air Insulin had only  paltry sales potential. She said investors should be focused instead on another  product Alkermes is developing with Lilly: a long-acting  formulation of Lilly’s Byetta diabetes treatment called Byetta    “We estimate that Byetta LAR could be worth $11 to $12 for  the (Alkermes) stock,” Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling  products, rose 2 cents to end at $49.70 on the New York Stock  Exchange, and was slightly lower at $49.67 in after-hours  trading.

SOLUTION: Eli Lilly drops inhaled insulin program.

PROBLEM: The Kate Spade New York Foundation said in a statement Wednesday it is donating $200,000 to The Jed Foundation, which partners with schools to strengthen mental health programs. The fashion brand will match public donations to JED from Wednesday through June 12, up to $100,000, at jedfoundation.org/katespade. The donations follow money already given to other organizations, including the Crisis Text Line. Anna Bakst, brand president and CEO of Kate Spade New York, said the company hopes to encourage more conversation, education and research around mental health. Spade killed herself June 5, 2018, at 55, after years of battling depression and anxiety.

SOLUTION: Kate Spade New York fulfills $1 million mental health pledge.

PROBLEM: In the first sessions of the day, people heard presentations on how activists could work together to push for Medicare for All, a system that would guarantee health care for everyone in the country, including a study on how it to pay the cost. “Only all that we love is on the line,” said Nina Turner, a fellow of the Sanders Institute, who expressed the fervor for universal health care felt by many at the meeting when she helped kicked off the first session. The meeting was held on the shores of Lake Champlain, an area that a half a century ago was grimy and industrial, but has  — in part because of Sanders’ work as mayor of Burlington in the 1980s — been converted into a public park in a vibrant small city with stunning views of New York’s Adirondack Mountains. The event is being hosted by The Sanders Institute, a think-tank formed last year separate from the senator’s political operations that grew out of the ideas generated during his 2016 presidential campaign. The institute and the meeting have attracted a number of high-profile supporters. Hollywood actors Danny Glover, Susan Sarandon, John Cusack and Cynthia Nixon joined intellectuals Cornel West and Simon Sinek. Elected officials such as Hawaii Rep. Tulsi Gabbard and New York Mayor Bill de Blasio are also expected at the meeting, which wraps up Saturday. The health care study released Friday morning that looked at Sanders’ 2017 Medicare for All Act. It estimated such a system would save an estimated 9.6 percent over current U.S. health care consumption expenditures, said University of Massachusetts economist Robert Pollin, one of the authors of the study. It estimates people would use an estimated 12 percent under a Medicare for All system. The savings would come from reducing administrative and pharmaceutical costs and establishing uniform Medicare rates for hospitals. Businesses would save about 8 percent of what they currently pay for employee health insurance. The system would need to raise just over $1 trillion in new government income to pay for it. Additional government revenue would come from a 3.75 percent sales tax on non-essential items and other taxes on the wealthiest people in the United States. “The biggest winners are going to be middle-class households,” Pollin said. People at the meeting did not address the prospects of the plan passing in Congress. The meeting comes as the 77-year-old Sanders is considering his political future. Sanders, who lost the 2016 Democratic nomination to Hillary Clinton, is expected to decide soon whether to launch a second bid for the White House. During a speech Thursday night, Sanders told supporters they had to work harder to convince people of all races, regions and income levels that liberal policies will help them. He also said that there has been a shift in the Democratic establishment which has increasingly embraced his calls for liberal policies such as universal health care and a $15 minimum wage.

SOLUTION:
Sanders Institute gathering a pep rally for liberal ideas.